Review
Nature Reviews Drug Discovery 3, 330-340 (April 2004) | doi:10.1038/nrd1342
Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention
Martin Braddock1 & Anthony Quinn2 About the authors
Abstract
The cytokine interleukin-1 (IL-1) is important in many human diseases, and drives a wide range of inflammatory responses in a number of cell types. Biological agents that target IL-1 neutralization have shown efficacy in patients with rheumatoid arthritis. Recently, new classes of compounds that target IL-1 production or processing, or regulatory steps on the IL-1 pathway, are being investigated as new drugs for the management of inflammatory disease. Such compounds will have wide utility in numerous inflammatory conditions.
- View At a Glance
Author affiliations
- Disease Sciences Section, Discovery Bioscience Department, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK.
- Department of Experimental Medicine, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK.
Correspondence to: Martin Braddock1 Email: martin.braddock@astrazeneca.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Osteoarthritis A single injection of anakinra for treating knee OA?Nature Reviews Rheumatology News and Views (01 Jul 2009)
RESEARCH
Fas ligation on macrophages enhances IL-1R1?Toll-like receptor 4 signaling and promotes chronic inflammationNature Immunology Article (01 Apr 2004)
See all 2 matches for Research
